Financial news regarding two major pharmaceutical companies – Allergan and Medicis – is positive lately, and analysts say it may be due to increased sales of injectable wrinkle treatments containing botulinum type a.
CNN reports that revenues for Dysport manufacturer Medicis last quarter represent an increase of over 30 percent compared with the same period in 2008. CEO Jonah Shacknai tells CNN Money: “We are encouraged by the positive physician and patient response to DYSPORT.” Although other new products have given Medicis a boost, a similar pattern is being seen with Botox manufacturer Allergan Inc.
With a 3 percent increase in Botox sales, “Allergan’s 3rd quarter profit rose 8.3 percent” reports the Wall Street Journal. New medical applications have the potential to increase use of Botox even further in the future, pending FDA approval of course.
Although there’s been a positive response to Dysport in Seattle, the brand awareness of Botox is still a major factor affecting sales, and that probably won’t change anytime soon.
This entry was posted on Thursday, November 5th, 2009 at 1:45 pm and is filed under Botox. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
